Pharma Companies in Flux Over Trump’s 200% Tariff Move on Generics

The US President Donald Trump’s announcement to impose tariffs on generic medicines imported from India has sent shockwaves through the global pharma industry. The plan, which escalates to 200% a year after August 2028, aims to “onshore” manufacturing and create jobs in the US.

However, beneath this rhetoric lies a complex web of implications that threaten not only India’s $30-billion pharma industry but also the affordability of essential medicines for millions of Americans. India supplies nearly 47% of generic prescriptions dispensed in the US, with exports totaling $10 billion annually. Higher prices of low-cost medicines could lead to shortages and reduced access to treatment for patients struggling with chronic diseases.

Industry insiders warn that 100-200% duties will make certain generic exports commercially unviable, squeezing margins and forcing companies to reassess their portfolios. “Two years is very short to do large product transfers,” Dr Reddy’s Labs co-chairman GV Prasad admitted candidly.

Companies like Sun Pharma, Dr Reddy’s Labs, Cipla, Lupin, Aurobindo Pharma, and Zydus Lifesciences, which generate significant revenue from the US market, will face immense pressure to adapt quickly. Analysts predict a decline in EBITDA margins by around 300-600 basis points.

The ambiguity surrounding the actual implementation of these tariffs adds to the uncertainty. This tariff move has echoes of past protectionist policies that have led to unintended consequences. The infamous Smoot-Hawley Tariff Act of 1930, for instance, is widely regarded as a contributing factor to the Great Depression. Similarly, Trump’s tariffs on Chinese goods have been criticized for exacerbating trade tensions and stifling economic growth.

India has already started its mitigation plan and is likely to engage with the US administration to build a stronger partnership. However, this may not be enough to alleviate the concerns of patients and pharma companies alike. As India’s pharmaceutical industry continues to grow in emerging markets like Brazil and Europe, it remains to be seen whether these tariffs will serve as a negotiating lever or an insurmountable obstacle.

The stakes are high. Patients, policymakers, and industry leaders must closely monitor this situation as it unfolds. Will the US administration reconsider its stance in light of the potential consequences? Or will Indian pharma companies be forced to adapt to an increasingly hostile environment? The world watches with bated breath as this drama unfolds.